Explore

Abortion pill makers ask US Supreme Court to restore mail-order access

Abortion pill makers ask US Supreme Court to restore mail-order access

By Ismail Shakil May 2 (Reuters) - Two drugmakers have asked the U.S. Supreme Court to restore mail-order access to mifepristone, a move that would continue to allow women access to one of the most widely used abortion methods pending ongoing legal challenges.

Supreme Court Asked to Maintain Mail Access for Abortion Drug Mifepristone

Supreme Court Asked to Maintain Mail Access for Abortion Drug Mifepristone

Danco Laboratories and GenBioPro have filed an emergency appeal to the Supreme Court, seeking to pause a lower court ruling that restricts mail-order access to the abortion drug mifepristone. The 5th U.S. Circuit Court of Appeals recently reinstated a requirement for in-person prescriptions, challenging the Biden administration's previous rule change that allowed mail distribution. Louisiana's lawsuit against the FDA argues that mail delivery of mifepristone facilitates illegal abortions and circumvents state bans. The appeals court's decision has prompted concerns about confusion and disruption in medical decision-making.

Supreme Court Asked to Maintain Mail-Order Access to Abortion Drug Mifepristone Amid Legal Challenges

Supreme Court Asked to Maintain Mail-Order Access to Abortion Drug Mifepristone Amid Legal Challenges

The Supreme Court is being petitioned to intervene in a legal dispute concerning the mail-order distribution of the abortion drug mifepristone. This follows a decision by the conservative 5th U.S. Circuit Court of Appeals, which temporarily reinstated a requirement for in-person prescriptions, a rule previously relaxed by the Biden administration. Louisiana, supported by other Republican-led states, argues that mail-order access to mifepristone facilitates illegal abortions and poses health risks such as sepsis and hemorrhaging. Drug manufacturers Danco Laboratories and GenBioPro have filed emergency appeals, urging the Supreme Court to pause the lower court's ruling, which they claim disrupts established medical practices and creates confusion among healthcare providers and patients.

Federal Court Blocks Mailing of Abortion Pill, Impacting Nationwide Access

Federal Court Blocks Mailing of Abortion Pill, Impacting Nationwide Access

A recent ruling by the 5th U.S. Circuit Court of Appeals has blocked the mailing of the abortion pill mifepristone, a decision that could significantly alter abortion access across the United States. The court's decision mandates that mifepristone, which was previously available via mail, must now be distributed in person at clinics. This ruling comes as a major victory for abortion opponents who argue that mail-order access undermines state bans on abortion. The decision has prompted Danco Laboratories, a manufacturer of mifepristone, to appeal to the Supreme Court to block the appellate court's ruling while further appeals are pending. The ruling affects all states, including those without abortion restrictions, and has sparked concerns about access for patients in remote areas.

US court blocks mail-order access to abortion drugs, for now

US court blocks mail-order access to abortion drugs, for now

By Daniel Wiessner May 1 (Reuters) - A U.S. appeals court on Friday temporarily blocked a federal rule allowing the abortion drug mifepristone to be dispensed through the mail, significantly curtailing access to the drug nationwide and particularly in states that have banned abortion.

Danco seeks Supreme Court stay of ruling that pauses mail-order access to abortion drugs

Danco seeks Supreme Court stay of ruling that pauses mail-order access to abortion drugs

By Ismail Shakil May 2 (Reuters) - Pharmaceutical company Danco Laboratories filed an application with the U.S. Supreme Court on Saturday seeking a stay of an appeals court ruling that temporarily blocks the abortion drug mifepristone from being dispensed through the mail.

Federal Appeals Court Restricts Abortion Pill Access, Requiring In-Person Pickup

Federal Appeals Court Restricts Abortion Pill Access, Requiring In-Person Pickup

A federal appeals court has temporarily reinstated a requirement that abortion pills, specifically mifepristone, be picked up in person rather than sent through the mail. This decision by the U.S. Court of Appeals for the 5th Circuit is seen as a victory for anti-abortion advocates. The ruling stems from a lawsuit filed by Louisiana against the FDA, challenging the agency's rule that allowed the distribution of abortion pills via telehealth and mail. The court's decision is in effect while the case continues, and it has prompted Danco Laboratories, a manufacturer of mifepristone, to file an emergency motion for a pause to seek a Supreme Court opinion. The ruling has significant implications for access to abortion, particularly affecting rural communities and those with limited resources.

Federal Appeals Court Restricts Mail-Order Access to Abortion Pill Mifepristone

Federal Appeals Court Restricts Mail-Order Access to Abortion Pill Mifepristone

A federal appeals court has issued a ruling that restricts the distribution of the abortion pill mifepristone by mail, mandating that it be dispensed only in person at clinics. This decision by the 5th U.S. Circuit Court of Appeals comes as a significant development in the ongoing legal battles over abortion access in the United States. The ruling challenges the FDA's regulations that previously allowed the pill to be prescribed via telehealth and mailed to patients, a practice that became more common during the COVID-19 pandemic. The court's decision is seen as a victory for abortion opponents who argue that mail-order access undermines state bans on abortion. The case is expected to be appealed to the Supreme Court, as Danco Laboratories, the manufacturer of mifepristone, has requested a stay on the ruling while appeals are pending.

Court restricts abortion access across the US by blocking the mailing of mifepristone

Court restricts abortion access across the US by blocking the mailing of mifepristone

A federal appeals court has restricted access to one of the most common means of abortion in the U.S. by blocking the mailing of mifepristone

Federal Court Blocks Mailing of Abortion Pill, Impacting U.S. Access

Federal Court Blocks Mailing of Abortion Pill, Impacting U.S. Access

A federal appeals court has issued a ruling that blocks the mailing of mifepristone, a widely used abortion pill, marking a significant shift in U.S. abortion policy. The 5th U.S. Circuit Court of Appeals' decision requires that mifepristone be distributed only in person at clinics, overturning previous FDA regulations that allowed for its prescription via telehealth. This ruling is seen as a victory for abortion opponents who argue that the pill's distribution undermines state bans on abortion. The decision affects all states, including those without abortion restrictions, and is expected to be appealed to the U.S. Supreme Court.

Federal Court Blocks Mail Distribution of Abortion Pill, Impacting Nationwide Access

Federal Court Blocks Mail Distribution of Abortion Pill, Impacting Nationwide Access

A federal court has blocked the distribution of the abortion pill mifepristone by mail, a decision that affects access to the drug across the United States. The ruling by the 5th U.S. Circuit Court of Appeals requires that mifepristone be distributed only in person and at clinics, overturning previous FDA regulations. This decision comes amid ongoing legal battles over abortion access following the overturning of Roe v. Wade. The ruling impacts patients in all states, including those without abortion restrictions, and has prompted manufacturers of the drug to seek emergency intervention from the Supreme Court.

Federal Appeals Court Blocks Mailing of Abortion Pill Mifepristone, Affecting Access Nationwide

Federal Appeals Court Blocks Mailing of Abortion Pill Mifepristone, Affecting Access Nationwide

A federal appeals court has issued a ruling that restricts the distribution of mifepristone, a common abortion pill, by blocking its mailing across the United States. The decision, made by a three-judge panel of the 5th U.S. Circuit Court of Appeals, mandates that mifepristone can only be dispensed in person at clinics, overturning previous regulations set by the Food and Drug Administration (FDA). This ruling follows the 2022 Supreme Court decision that overturned Roe v. Wade, allowing states to enforce abortion bans. The court's decision is based on the argument that mailing the drug undermines state laws banning abortion, as highlighted by Judge Kyle Duncan, appointed by President Trump. Mifepristone, approved in 2000, is used in combination with misoprostol for early pregnancy terminations and is involved in the majority of abortions in the U.S. The ruling is expected to be appealed to the U.S. Supreme Court.